Latest

CytoDyn names Robert Hoffman CEO, moves Lalezari to research role

CytoDyn said Robert E. Hoffman becomes CEO effective October 20, 2026, as Jacob Lalezari shifts to lead research on leronlimab in solid-tumor oncology.

SEC filing